Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

117m Sn DTPA

Drug Profile

117m Sn DTPA

Alternative Names: Pentetate 117m Sn; Stanamet; Tin-117m DTPA

Latest Information Update: 05 Jun 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nonindustrial source
  • Developer Bayer Schering Pharma; Nonindustrial source
  • Class Analgesics; Radiopharmaceuticals
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Bone cancer; Cancer pain

Most Recent Events

  • 17 Jun 2004 Discontinued - Phase-II for Cancer pain in USA (unspecified route)
  • 16 Nov 1999 Diatide has been acquired by Schering AG
  • 01 Jul 1999 The US Department of Energy will give Brookhaven National Laboratory US$750,000 over 3 years to develop Stanamet
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top